Prostate Cancer Clinical Trial
Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
The purpose of this study is to test the safety and side effects "of "ultra-hypofractionated" radiation therapy when used after brachytherapy (radiation implants). This treatment delivers a higher radiation dose with each treatment over a shorter period of time.
Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as:
Pathologically-proven diagnosis of prostate adenocarcinoma
PSA 10-20ng/mL or
Gleason =7 or
Clinical stage T2b/c
Clinical stage T2b/c Additionally, patients will be required to meet the following criteria
Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician.
International Prostate Symptom Score ≤15
Prior prostate surgery (including TURP)
Prior history of chronic prostatitis or urethral stricture
Inflammatory bowel disease
Prior history of pelvic radiotherapy
Unable to give informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Basking Ridge New Jersey, 07920, United States
Commack New York, 11725, United States
Harrison New York, 10604, United States
New York New York, 10065, United States
Rockville Centre New York, , United States
Uniondale New York, 11553, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.